A Phase 1a/1b Study of an Anti-IDO-1 Agent (LY3381916) Administered Alone or in Combination with Anti-PD-L1 Checkpoint Antibody (LY3300054) in Solid Tumors
Study Overview
The purpose of this study is to evaluate the safety of the study drug LY3381916 administered alone or in combination with anti-programmed cell death ligand 1 (PD-L1) checkpoint antibody (LY3300054).
Study Description
The purpose of this study is to evaluate the safety of the study drug LY3381916 administered alone or in combination with anti-programmed cell death ligand 1 (PD-L1) checkpoint antibody (LY3300054).
Additional Information
Participants will be compensated for their participation.
- IRB Number: 1708847726 (I9L-MC-JZCA)
- Research Study Identifier: TX8313
- Principal Investigator: Shadia Jalal, MD
Recruitment Status
OpenContact the research team to learn more about this study.
Fields marked with asterisk (*) are required
